Anemia Clinical Trials

Find Anemia Clinical Trials Near You

The Role of 7.2% Amino Acids in Improving Nutritional Status in Patients With Chronic Kidney Disease Undergoing Hemodialysis: A Retrospective Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Malnutrition and anemia are common among people with chronic kidney disease who receive maintenance hemodialysis. These conditions may worsen health outcomes and quality of life. Intradialytic parenteral nutrition (IDPN) provides nutrients through a vein during hemodialysis and may be used when dietary intake is not sufficient. However, evidence on IDPN containing only amino acids, particularly in adults undergoing hemodialysis in Indonesia, remains limited. This retrospective observational study will evaluate whether a 7.2% amino acid solution (KIDMIN®) given as IDPN is associated with improved nutritional status in adults with chronic kidney disease receiving maintenance hemodialysis. Medical records from Bangli Medika Canti Hospital covering July 2023 through December 2024 will be reviewed. Patients who received KIDMIN® during hemodialysis for at least 3 months will be compared with patients who did not receive IDPN. Both groups received the standard diet recommended for chronic kidney disease. The main outcome is the change in serum albumin level from baseline to Month 3. Other outcomes include serum albumin through Month 6, hemoglobin levels, nutritional status assessed using the Subjective Global Assessment, and quality of life assessed using the Kidney Disease Quality of Life questionnaire. No study-specific medication or additional invasive procedure will be administered because the study uses previously available clinical data.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years.

• Outpatients undergoing maintenance hemodialysis at Bangli Medika Canti Hospital who are clinically stable and are not experiencing any acute condition.

• Confirmed malnutrition, defined as a condition resulting from insufficient or imbalanced intake of energy, protein, and/or other nutrients, which may adversely affect body composition, physical and mental function, and clinical outcomes, and meeting all of the following criteria within 1-7 days:

‣ Body Mass Index (BMI) less than 18.5 kg/m2

⁃ Mid-upper arm circumference (MUAC) less than 24.5 cm

⁃ Serum pre-albumin level less than 16 mg/dL

• Confirmed anemia, defined as a hemoglobin (Hb) concentration below the normal reference range within 1-7 days, specifically an Hb level of less than 13.0 g/dL in male patients or less than 12.0 g/dL in female patients.

• At least 3 months of maintenance haemodialysis with duration of 3-4 hours per session, 2-3 times per week.

• Provision of written informed consent prior to enrollment in this study (patient is available, can be contacted and approached).

Locations
Other Locations
Indonesia
Bangli Medika Canti Hospital
RECRUITING
Bangli
Contact Information
Primary
Dini Arini, MD
dadea441@gmail.com
62217654466
Time Frame
Start Date: 2026-07-25
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 90
Treatments
IDPN Group
Patients undergoing maintenance hemodialysis who receive IDPN during the hemodialysis procedure. IDPN administration is initiated 1-1.5 hours before the end of each dialysis session. The product used is KIDMIN® 200 mL injection, administered for a minimum period of 3 months.
Control Group
Patients undergoing maintenance hemodialysis who do not receive IDPN.
Related Therapeutic Areas
Sponsors
Leads: PT Otsuka Indonesia

This content was sourced from clinicaltrials.gov